Pregnancy, heparin and osteoporosis.
Schulman
Sam
S
Department of Hematology, Karolinska Hospital, Stockholm, Sweden. sam.schulman@ks.se
Hellgren-Wångdahl
Margareta
M
D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D002116:Calcitonin / Q000097:blood; D002118:Calcium / Q000097:blood; D016022:Case-Control Studies; D018592:Cross-Over Studies; D005260:Female; D005269:Femur / Q000737:chemistry / Q000187:drug effects; D005500:Follow-Up Studies; D006493:Heparin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008159:Lumbar Vertebrae / Q000737:chemistry / Q000187:drug effects; D010024:Osteoporosis / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000517:prevention & control*; D011644:Puerperal Disorders / Q000097:blood / Q000139:chemically induced* / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D013923:Thromboembolism / Q000517:prevention & control*
D000925:Anticoagulants; D006493:Heparin; D002116:Calcitonin; D002118:Calcium